ATZ1993, an Orally Active and Novel Nonpeptide Antagonist for Endothelin Receptors and Inhibition of Intimal Hyperplasia After Balloon Denudation of the Rabbit Carotid Artery

この論文にアクセスする

この論文をさがす

著者

    • Sato Jun SATO Jun
    • Department of Molecular Design, Institute of Biomedicals & Bioengineering, Tokyo Medical & Dental University
    • GOTO Moritaka
    • Department of Molecular Design, Institute of Biomedicals & Bioengineering, Tokyo Medical & Dental University
    • TAMAOKI Satoru
    • Department of Molecular Design, Institute of Biomedicals & Bioengineering, Tokyo Medical & Dental University
    • SUGIMOTO Akiko
    • Department of Molecular Design, Institute of Biomedicals & Bioengineering, Tokyo Medical & Dental University
    • HAMASAKI Hidehisa
    • Pharmacology and Organic Chemistry Research Departments, Teikoku Hormone MFG.
    • YAMASHITA Haruo
    • Pharmacology and Organic Chemistry Research Departments, Teikoku Hormone MFG.

抄録

The present experiments were designed to investigate the effect of ATZ1993 {3-carboxy-4, 5-dihydro-1-[1-(3-ethoxyphenyl)propyl]-7-(5-pyrimidinyl)methoxy-[1<I>H</I>]-benz[<I>g</I>]indazole} on the intimal hyperplasia after balloon endothelial denudation of the rabbit carotid artery. ATZ1993 inhibited the specific [<SUP>125</SUP>I]endothelin (ET)-1 binding not only to ET-receptor subtype A (ET<SUB>A</SUB>) with a pK<SUB>i</SUB> value of 8.69±0.02, but also to ET-receptor subtype B (ET<SUB>B</SUB>) with a pK<SUB>i</SUB> value of 7.20±0.03. Counterscreening in the binding assay (30 different receptors) confirmed that ATZ1993 had a high selectivity for ET receptors. Increases in intima:media ratio and DNA content in the vessel wall were significantly (P<0.005) inhibited by ATZ1993 in a daily dose of 30 mg·200 ml<SUP>-1</SUP>·kg<SUP>-1</SUP> for 1 week before and 6 weeks after balloon denudation. Inhibition of the intimal hyperplasia with ATZ1993 was determined as approximately 77% for increases in intima:media ratio and DNA content. Plasma concentrations of ATZ1993 ranged between 121.6±26.6 and 131.7±20.9 nM throughout experimental periods. Mean arterial blood pressure, heart rate and body weight gain remained unaffected by administering ATZ1993. These results demonstrate that ATZ1993 is a novel nonpeptide and nonselective ET<SUB>A</SUB>/ET<SUB>B</SUB>-receptor antagonist, and the agent when administered orally inhibits effectively intimal hyperplasia after balloon denudation of the rabbit carotid artery.

収録刊行物

  • The Japanese journal of pharmacology

    The Japanese journal of pharmacology 81(1), 21-28, 1999-09

    公益社団法人 日本薬理学会

参考文献:  30件中 1-30件 を表示

各種コード

  • NII論文ID(NAID)
    10008196045
  • NII書誌ID(NCID)
    AA00691188
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    00215198
  • NDL 記事登録ID
    4867767
  • NDL 雑誌分類
    ZS51(科学技術--薬学)
  • NDL 請求記号
    Z53-D199
  • データ提供元
    CJP書誌  NDL  J-STAGE 
ページトップへ